Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
Stanley C. Jordan, P. Zakowski, Hai Tran, et al.
Clinical Infectious Diseases (2020) Vol. 71, Iss. 12, pp. 3168-3173
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone, Matthew J. Frigault, Naomi Serling‐Boyd, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 24, pp. 2333-2344
Open Access | Times Cited: 1311
STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
Robbert Boudewijns, Hendrik Jan Thibaut, Suzanne J. F. Kaptein, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 273
COVID-19 and Cancer: Current Challenges and Perspectives
Ziad Bakouny, Jessica E. Hawley, Toni K. Choueiri, et al.
Cancer Cell (2020) Vol. 38, Iss. 5, pp. 629-646
Open Access | Times Cited: 257
Targeting IL-6 trans-signalling: past, present and future prospects
Stefan Rose‐John, Brendan J. Jenkins, Christoph Garbers, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 10, pp. 666-681
Open Access | Times Cited: 231
SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells
Tapas Patra, Keith Meyer, Lizzie Geerling, et al.
PLoS Pathogens (2020) Vol. 16, Iss. 12, pp. e1009128-e1009128
Open Access | Times Cited: 200
Neutralizing antibodies for the prevention and treatment of COVID-19
Lanying Du, Yang Yang, Xiujuan Zhang
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 10, pp. 2293-2306
Open Access | Times Cited: 117
The role of Interleukin 6 inhibitors in therapy of severe COVID-19
Е. Л. Насонов, Samsonov MIu
Biomedicine & Pharmacotherapy (2020) Vol. 131, pp. 110698-110698
Open Access | Times Cited: 110
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo A. Ascierto, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 108
Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses
Stanley C. Jordan
Clinical & Experimental Immunology (2021) Vol. 204, Iss. 3, pp. 310-320
Open Access | Times Cited: 84
Predictors and outcomes of healthcare-associated infections in COVID-19 patients
Gagan Kumar, Alex Adams, Martin Hererra, et al.
International Journal of Infectious Diseases (2020) Vol. 104, pp. 287-292
Open Access | Times Cited: 75
Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2
Fakry F. Mohamed, Darisuren Anhlan, Michael Schöfbänker, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 530-530
Open Access | Times Cited: 39
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
Avi Kaye, Robert D. Siegel
PeerJ (2020) Vol. 8, pp. e10322-e10322
Open Access | Times Cited: 58
COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations
Bin Zhou, Shinsuke Kojima, Atsuhiko Kawamoto, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 5, pp. 2694-2704
Open Access | Times Cited: 51
Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
Edmund Huang, Stanley C. Jordan
New England Journal of Medicine (2020) Vol. 383, Iss. 24, pp. 2387-2388
Open Access | Times Cited: 50
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19
Shikha Patel, Bhagawati Saxena, Priti Mehta
Heliyon (2021) Vol. 7, Iss. 2, pp. e06158-e06158
Open Access | Times Cited: 49
Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets
Rittibet Yapasert, Patompong Khaw-on, Ratana Banjerdpongchai
Molecules (2021) Vol. 26, Iss. 24, pp. 7459-7459
Open Access | Times Cited: 49
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Jiaying Shen, Junyan Fan, Yue Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Comparison of effectiveness and safety between baricitinib and tocilizumab in severe COVID-19. A retrospective study
Ioannis Tomos, Ioannis Grigoropoulos, Chrysavgi Kosti, et al.
Expert Review of Respiratory Medicine (2025), pp. 1-9
Closed Access
Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis
Qi Han, Mingyue Guo, Yue Zheng, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 40
Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis
Manuel Rubio‐Rivas, Carlos G. Forero, José María Mora‐Luján, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2021) Vol. 41, Iss. 11, pp. 884-906
Open Access | Times Cited: 35
Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study
Manab Mandal, Swapan K. Chowdhury, Abdul Ashik Khan, et al.
Journal of Molecular Structure (2021) Vol. 1234, pp. 130152-130152
Open Access | Times Cited: 33
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis
Soheila Rezaei, Behzad Fatemi, Zahra Karimi Majd, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 5, pp. 499-511
Open Access | Times Cited: 33
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo A. Ascierto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 36
SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment
Khalil Khalaf, Natalia Papp, Jadzia Tin-Tsen Chou, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 36
Aberrant cytokine expression in COVID-19 patients: Associations between cytokines and disease severity
Yueting Tang, Jiayu Sun, Huaqin Pan, et al.
Cytokine (2021) Vol. 143, pp. 155523-155523
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top